(J Am
Vet Med Assoc 2013;242:322-334)”
“Polaprezinc, a chelate compound consisting of zinc and L-carnosine, is clinically used as a medicine for gastric ulcers. It has been shown that induction of heat shock protein (HSP) is involved in protective effects of polaprezine against gastric mucosal injury. In the present study, we investigated whether polaprezinc and its components could induce HSP70 and prevent acetaminophen (APAP) toxicity in mouse primary cultured hepatocytes. Hepatocytes were treated with polaprezine, zinc sulfate or L-carnosine at the concentration of 100 mu M for 9 h, and then exposed to 10 mM APAP. Polaprezinc Oligomycin A mouse or zinc sulfate increased cellular HSP70 expression. However, L-carnosine had no influence on it. Pretreatment of the cells with polaprezine or zinc sulfate significantly suppressed cell death as well as cellular lipid peroxidation after APAP treatment. In contrast, pretreatment with polaprezinc did not affect decrease in intracellular glutathione after APAP. Furthermore, treatment with KNK437, an HSP inhibitor, attenuated increase in HSP70 expression induced by polaprezinc, and abolished protective effect of polaprezine on cell death after APAP. These results suggested that polaprezinc, in particular its zinc component, induces HSP70 expression in mouse primary cultured hepatocytes, and inhibits lipid peroxidation
after APAP treatment, resulting in protection against APAP toxicity.”
“Patients with mixed dyslipidemia have a higher Apoptosis inhibitor risk of atherosclerotic coronary heart disease than patients with isolated elevated LDL-C. Evidence-based guidelines target LDL-C reduction and other lifestyle factors to reduce risk. However, patients with mixed dyslipidemia have a high risk of vascular events, even with statin treatment to optimal LDL-C levels. Available treatments for other modifiable lipid factors,
such as elevated triglycerides and reduced HDL-C, are underutilized Alvocidib in vitro in such patients since there are no large-scale clinical outcomes trials showing incremental benefit, as well as clinician concerns regarding safety with combination treatment. Recent efficacy and safety trials have demonstrated that the combination of fenofibric acid and a statin improves multiple lipid parameters in patients with mixed dyslipidemia without additional safety concerns compared with the individual monotherapies. Ongoing surrogate and event outcomes trials are testing the incremental benefit of such a combination treatment strategy.”
“Objective-To compare the cardiorespiratory effects of IM administration of dexmedetomidine-buprenorphine (DB) and dexmedetomidine-buprenorphine-ketamine (DBK) in dogs with subsequent reversal with atipamezole.
Design-Prospective, randomized crossover study.
Animals-5 healthy dogs.